Navigation Links
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Date:10/23/2008

and these data further substantiate its attractiveness as a molecule for treating cancer and potentially BPH," said Dr. Urdal. "We look forward to filing an investigational new drug application with the U.S. Food and Drug Administration later this year to evaluate the compound in a Phase 1 dose escalation study in cancer."

About Trp-p8

Trp-p8 (also known as Trp-M8) was identified through Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures and small-molecule agonists. In normal human tissues Trp-p8 is expressed predominantly in the prostate where it is over-expressed in BPH and prostate cancer, as well as a range of other cancers including breast, lung and colon. Dendreon has synthesized bioavailable small molecule agonists that activate the Trp-p8 ion channel and induce cell death.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the proc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Dendreon Reports First Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Announces Closing of Registered Direct Offering
7. Dendreon Announces $47 Million Registered Direct Offering
8. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
9. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
10. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
(Date:9/30/2014)... September 30, 2014 Applying a well-known optical ... at Harvard University has demonstrated the ability to ... work that holds promise for making future, flexible ... the sides of next-gen rocket ships and spacecraft ... passes through oil in water, it becomes iridescent, ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Six new stem cell therapies, all forecast to reach physicians ... Summit on February 16 in New York City. These new therapies ... at least one FDA-approved stem cell drug. New studies showing rehydration ... are also on the agenda. , The Stem Cell Summit is ...
... REHOVOT, Israel, December 31 D-Pharm Ltd ... its,Phase III clinical study of DP-b99 (MACSI). The first patient ... trial involves,numerous medical centers in the US, Canada, Europe, Israel, ... product developed,for protection of brain cells suffering from restricted blood ...
... ... For The Massachusetts Biotechnology Council , ... Boston, MA (PRWEB) December 31, 2009 -- Social Media ... Biotechnology Council’s (MassBio) has selected the Boston-based Social Media Marketing Agency to plan and ...
Cached Biology Technology:5th Annual Summit to Feature New Stem Cell Therapies 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 2 The Massachusetts Biotechnology Council Selects Social Media Marketing Agency 451 Marketing To Develop A Social Media Strategy For 2010 3
(Date:9/30/2014)... the Mediterranean each year, but its deep-blue waters ... Almost 1,000 alien species, including fish, crustaceans, and ... human activities. In the open-access journal Frontiers ... researchers analyzed data from a new information system ... the introduction of alien species has changed the ...
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... 2014--Sea monkeys have captured the popular attention of both ... life cycle -- sold as dehydrated eggs, these tiny ... more than a tank of salt water. , ... other zooplankton, brine shrimp vertically migrate in large groups ... the surface at night and retreating deeper during the ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... After a decade and a half of near stagnation, ... chronic illness instead of a terminal disease, a leading Colorado ... drugs have different and innovative methods of action. One is ... another is radiotherapy; and the final one is the first ...
... ingredient in the food industry because of its association with ... the February issue of the Journal of Food Science ... fish oil can be added to goat cheese to deliver ... or shelf-life. Fish oil delivers higher levels and more ...
... Republic of Congo has formally expanded Nouabal-Ndoki National Park ... most pristine forests and a population of "nave" chimpanzees ... apes investigate the conservationists who study them rather than ... 100-plus square-mile dense swamp forest and its unique great ...
Cached Biology News:4 new drugs will change prostate cancer care 2Great news for chimpanzees 2Great news for chimpanzees 3
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
...
... revolutionary new application for DNA and ... interface, Expression makes complex computational analyses ... uses the very latest computing technology ... way sequences are analysed. Features include: ...
... Partek Genomics Solution is a ... interactive data visualization specifically designed to ... Designed for high-dimensional genomic studies containing ... is fast, memory efficient and will ...
Biology Products: